SE0002202D0 - New peptides - Google Patents

New peptides

Info

Publication number
SE0002202D0
SE0002202D0 SE0002202A SE0002202A SE0002202D0 SE 0002202 D0 SE0002202 D0 SE 0002202D0 SE 0002202 A SE0002202 A SE 0002202A SE 0002202 A SE0002202 A SE 0002202A SE 0002202 D0 SE0002202 D0 SE 0002202D0
Authority
SE
Sweden
Prior art keywords
new peptides
alkylating
invention refers
peptides
new
Prior art date
Application number
SE0002202A
Other languages
English (en)
Swedish (sv)
Inventor
Rolf Lewensohn
Joakim Gullbo
Rolf Larsson
Hans Ehrsson
Kristina Luthman
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE0002202A priority Critical patent/SE0002202D0/xx
Publication of SE0002202D0 publication Critical patent/SE0002202D0/xx
Priority to PCT/SE2001/001318 priority patent/WO2001096367A1/en
Priority to AT01938945T priority patent/ATE458746T1/de
Priority to AU2001264515A priority patent/AU2001264515A1/en
Priority to EP01938945A priority patent/EP1290011B1/en
Priority to PT01938945T priority patent/PT1290011E/pt
Priority to DK01938945.1T priority patent/DK1290011T3/da
Priority to ES01938945T priority patent/ES2341702T3/es
Priority to DE60141398T priority patent/DE60141398D1/de
Priority to CA2408501A priority patent/CA2408501C/en
Priority to US10/297,588 priority patent/US6992207B2/en
Priority to JP2002510508A priority patent/JP4798930B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0002202A 2000-06-13 2000-06-13 New peptides SE0002202D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE0002202A SE0002202D0 (sv) 2000-06-13 2000-06-13 New peptides
JP2002510508A JP4798930B2 (ja) 2000-06-13 2001-06-11 メルファラン誘導体及び癌の化学療法薬としてのその使用
EP01938945A EP1290011B1 (en) 2000-06-13 2001-06-11 Melphalan derivatives and their use as cancer chemotherapeutic drugs
AT01938945T ATE458746T1 (de) 2000-06-13 2001-06-11 Melphalan-derivate und ihre verwendung als chemotherapeutika gegen krebs
AU2001264515A AU2001264515A1 (en) 2000-06-13 2001-06-11 Melphalan derivatives and their use as cancer chemotherapeutic drugs
PCT/SE2001/001318 WO2001096367A1 (en) 2000-06-13 2001-06-11 Melphalan derivatives and their use as cancer chemotherapeutic drugs
PT01938945T PT1290011E (pt) 2000-06-13 2001-06-11 Derivados de melfalano e seu uso como drogas quimioterapêuticas de cancro
DK01938945.1T DK1290011T3 (da) 2000-06-13 2001-06-11 Melphalan-derivater og deres anvendelse som cancer-kemoterapeutiske lægemidler
ES01938945T ES2341702T3 (es) 2000-06-13 2001-06-11 Derivados de melfalan y su uso como farmacos quimioterapeuticos del cancer.
DE60141398T DE60141398D1 (de) 2000-06-13 2001-06-11 Melphalan-derivate und ihre verwendung als chemotherapeutika gegen krebs
CA2408501A CA2408501C (en) 2000-06-13 2001-06-11 Melphalan derivatives and their use as cancer chemotherapeutic drugs
US10/297,588 US6992207B2 (en) 2000-06-13 2001-06-11 Melphalan derivatives and their use as cancer chemotherapeutic drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0002202A SE0002202D0 (sv) 2000-06-13 2000-06-13 New peptides

Publications (1)

Publication Number Publication Date
SE0002202D0 true SE0002202D0 (sv) 2000-06-13

Family

ID=20280067

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0002202A SE0002202D0 (sv) 2000-06-13 2000-06-13 New peptides

Country Status (10)

Country Link
EP (1) EP1290011B1 (ja)
JP (1) JP4798930B2 (ja)
AT (1) ATE458746T1 (ja)
AU (1) AU2001264515A1 (ja)
CA (1) CA2408501C (ja)
DK (1) DK1290011T3 (ja)
ES (1) ES2341702T3 (ja)
PT (1) PT1290011E (ja)
SE (1) SE0002202D0 (ja)
WO (1) WO2001096367A1 (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1374907A3 (en) * 2002-06-24 2004-01-07 Ghanem Elias c/o Institut Jules Bordet Ghanem Drug transport and delivery system
DE10239832A1 (de) * 2002-08-29 2004-03-18 Lipal Biochemicals AG c/o University of Zurich Sarcolysyl-Derivate und Verfahren zu deren Herstellung
WO2011011865A1 (en) * 2009-07-29 2011-02-03 3R Valo, S.E.C. Anticancer agents based on amino acid derivatives
WO2011078782A1 (en) * 2009-12-22 2011-06-30 Oncopeptides Ab A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer
PT3656393T (pt) 2011-04-28 2022-11-03 Oncopeptides Ab Preparação liofilizada de dipéptidos citotóxicos
HUE051690T4 (hu) * 2011-04-28 2023-09-28 Oncopeptides Ab Citotoxikus dipeptidek liofilizált készítménye
ES2768268T3 (es) * 2012-10-26 2020-06-22 Oncopeptides Ab Preparaciones liofilizadas de melfalán flufenamida
CA2889753C (en) * 2012-10-26 2021-03-02 Oncopeptides Ab Lyophilized preparations of melphalan flufenamide
GB201507903D0 (en) * 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
CN108864251B (zh) * 2018-06-30 2022-06-14 大连理工大学 一类氨肽酶n激活的药物前体化合物及其制备方法和应用
SG11202103726RA (en) * 2018-10-18 2021-05-28 Oncopeptides Ab Compounds containing deuterium
CN114025753A (zh) 2019-04-03 2022-02-08 肿瘤多肽有限公司 用美氟芬治疗al淀粉样变性
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
WO2022167087A1 (en) * 2021-02-05 2022-08-11 Oncopeptides Ab Peptidase enhanced cytotoxic dipeptides
EP4083052A1 (en) 2021-04-29 2022-11-02 BKmdcl AB Peptide conjugates of melphalan for the treatment of cancer
EP4347615A1 (en) 2021-06-01 2024-04-10 Synthon B.V. Process for making melflufen or a salt thereof
WO2023281007A1 (en) 2021-07-08 2023-01-12 Oncopeptides Ab Melflufen for use in the treatment of multiple myeloma
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines

Also Published As

Publication number Publication date
CA2408501C (en) 2011-01-18
ES2341702T3 (es) 2010-06-25
JP4798930B2 (ja) 2011-10-19
ATE458746T1 (de) 2010-03-15
JP2004503564A (ja) 2004-02-05
EP1290011B1 (en) 2010-02-24
EP1290011A1 (en) 2003-03-12
PT1290011E (pt) 2010-05-11
WO2001096367A1 (en) 2001-12-20
DK1290011T3 (da) 2010-06-07
AU2001264515A1 (en) 2001-12-24
CA2408501A1 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
SE0002202D0 (sv) New peptides
BR9713404A (pt) ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos.
HUP0300299A2 (hu) Szabad aminosavakat tartalmazó kompozíció
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
DZ3197A1 (fr) Acides aminés bicycliques utilises comme agents pharmaceutiques.
NZ593815A (en) Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
WO2004091497A3 (en) Methods and compositions for increasing the anaerobic working capacity in tissues
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
WO2001068645A3 (en) N-cyanomethylcarboxamides and their use as protease inhibitors
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
WO2002062304A3 (de) Kosmetische und/oder pharmazeutische mittel acylierte aminosäure und proteinkondensat enthaltend.
NO955067D0 (no) FVII/TF peptider
EP1774966A4 (en) MEANS TO INHIBIT THE USE AND PROGRESS OF LIVER CANCER IN PATIENTS WITH HEPATITIS C-VIRUS POSITIVE LIVER CIRR
WO2005002500A3 (en) Inhibitors of coronavirus
HUP0202729A2 (hu) Ösztramusztin-foszfátot és aminosavakat tartalmazó, parenteralis felhasználásra szolgáló készítmények
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
IT1318556B1 (it) Composizione farmaceutica a base di prolina, glicina e lisina utilenella terapia per la cicatrizzazione delle ferite e delle lesioni
ATE371737T1 (de) Proteaseresistente flint-analoge
MXPA02001268A (es) Antagonistas de il-16.
FI942938A (fi) Soijaproteiini tai -hydrolysaatit farmaseuttisissa koostumuksissa bioaktiivisten peptidien suojana entsymaattista inaktivoitumista vastaan
ATE281522T1 (de) Sentrin-spezifische menschliche protease senp1
WO2003025014A3 (fr) Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes